Armune BioScience Expands Commercial Team in Preparation for Launch of Apifiny
Wednesday, May 28, 2014
David Esposito appointed as Chief Operating Officer to support market launch
Armune BioScience, Inc. today announced that it has appointed David Esposito as the company’s Chief Operating Officer. In the newly created role, David will be responsible for the commercial strategy for Apifiny® and planned expansion of the company’s sales and marketing efforts.
"As Armune BioScience prepares to commercialize the first of what will be a number of promising diagnostic and prognostic technologies, we are pleased that David Esposito has joined the Armune BioScience team to support our plans,” commented Eli Thomssen, President & CEO of Armune BioScience. “David brings a wealth of experience in the diagnostic and pharmaceutical markets and we look forward to his leadership in helping Armune BioScience reach our full potential.”
David has a tremendous amount of commercial experience as a senior executive in both the pharmaceutical and medical diagnostic markets. Over a 15-year career with Merck & Co., David played key roles in sales, marketing, and commercial strategy. David, as the former President and General Manager of Phadia US Inc., a leading specialty diagnostics company, helped drive significant growth in the US market and was a key member of the Phadia Leadership Team that successfully sold the business to Thermo Fisher Scientific for $3.5 Billion USD in 2011. Prior to his work in the healthcare marketplace, David graduated from the United States Military Academy at West Point with a BS in Civil Engineering. David is a combat veteran having served as an infantry platoon leader with the 101st Airborne Division and was awarded the Bronze Star Medal during the Persian Gulf War. David also holds a Master of Business Administration from Syracuse University.
David Esposito commented on joining Armune BioScience, "I am grateful to be joining the team at Armune BioScience at such an exciting time as we prepare to commercialize Apifiny®, a prostate cancer diagnostic assay that will be the first of many breakthrough diagnostic tests. The proprietary technologies of Armune BioScience have significant potential to meet areas of large unmet need in prostate, lung, and breast cancer diagnostic and prognostic testing. I look forward to helping the team prepare and execute on the commercial opportunities.”
Armune BioScience is currently focused on raising $7.5 million to prepare for market launch and fund an R&D program to develop additional cancer diagnostic tests.
This round of fund raising combined with successfully executing the company’s launch plans for Apifiny® should provide adequate resources towards the company’s sustainability.
About Armune BioScience
Armune BioScience, Inc. is a medical diagnostics company formed to develop and commercialize unique proprietary technology exclusively licensed from the University of Michigan for diagnostic and prognostic tests for prostate, lung and breast cancers. The Company was founded by the Apjohn Group, LLC, a business accelerator founded by experienced health care executives that brings together valuable resources of management talent and angel/seed financing, and a group of experienced life science professionals. Armune was incorporated as a Delaware Corporation with corporate headquarters in Kalamazoo, MI and a research and commercial laboratory facility in Ann Arbor, MI.